By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

Generic Name

Pembrolizumab

Brand Name

Keytruda
Merck

Product Monograph

Stage I, Stage II, Stage III
Triple Negative
Immunotherapy
Injectable
Listed on Provincial/Territorial drug Formulary

The process of getting a drug approved and publicly funded in Canada is complex and lengthy. CBCN has created an infographic on how drugs get funded in Canada to make understanding Canada’s drug approval process a little easier. Access the infographic here.

Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Québec, Saskatchewan, Yukon
No
Yes

Merck Care Oncology Program
Monday to Friday from 8 am to 8 pm ET
Phone: 1-855-549-9416
Fax: 1-855-549-9415
Email: keytruda@bayshore.ca

Merck Canada offers a number of patient support programs designed to help patients by providing services and secure access to the treatment prescribed by their Healthcare Professional. These programs are available to eligible patients through their Healthcare Professional. To confirm eligibility, patients should contact their Healthcare Professional.